Trial Profile

Phase I/ll Dose-escalation Study of Fractionated Dose 177Lu-PSMA-617 for Progressive Metastatic Castration Resistant Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Gallium (68Ga) gozetotide
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions

Most Recent Events

04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
30 Oct 2023 Planned End Date changed from 1 Sep 2023 to 1 Dec 2025.
13 Sep 2022 Results (n=80) assessing the real-time tissue biopsies in the setting of mCRPC presents challenges that might be overcome with the use of ctDNA by collecting data from NCT03042468 and NCT03276572, presented at the 47th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com